For example, poly(ADP-ribose) polymerase (PARP) inhibitors in breast cancer gene 1 (BRCA1) or BRCA2 mutated ovarian cancers exploit this cancer intrinsic vulnerability and lead to synthetic lethal interactions with clinical relevance [8, 9]. The gene discussed is BRCA1; the disease is ovarian carcinoma.